The medical community has its eyes on a promising new drug that’s offering a glimmer of hope for people with chronic lymphocytic leukemia (CLL) who have weathered several rounds of treatment. Coming out of the University of Cincinnati Cancer Center, the trial for a novel drug dubbed bexobrutideg is delivering some noteworthy early results.
Dr. Zulfa Omer, a Cancer Center member and assistant professor at the UC College of Medicine, spearheaded the research, examining bexobrutide’s on-target engagement with the BTK enzyme in patients already burdened by extensive CLL treatments. A presentation made at the 2025 European Hematology Association Congress, and as reported by Cancer Network News, highlighted that out of 48 patients enrolled, the majority responded favorably to the drug.
The statistics are telling: a significant 80.9% hit an “objective response,” either completely or partially pushing back against their cancer’s march. Meanwhile, seven patients found themselves in a holding pattern with stable disease, and only two saw their CLL press on despite taking bexobrutideg. As the report from the trial known as Phase 1 NX-5948-301 suggests, this isn’t a bout with a light jab; it’s potentially a heavy-hitting contender in the fight against CLL…